Paper Details

  1. Home
  2. Paper Details

Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS.

Author: AschmannHélène E, KesselringJürg, PuhanMilo A, SpanuAlessandra

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluates the benefit-harm balance of fingolimod, a medication for multiple sclerosis (MS), using individual patient data from a randomized controlled trial.
Paper Details　
Original Abstract of the Article :
Fingolimod lowers the number of relapses in multiple sclerosis (MS) patients and slows down disease progression, but causes a broad spectrum of side effects. Our aim was to estimate the benefit-harm balance of fingolimod using individual patient data from FREEDOMS, a randomized controlled trial that...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.msard.2020.102464

データ提供：米国国立医学図書館（NLM）

Fingolimod in MS: Balancing Benefits and Harms

This study explores the complexities of fingolimod, a medication used to treat multiple sclerosis (MS). It's like navigating a desert with shifting sands, understanding the potential benefits and risks of this treatment option. The researchers, like cartographers, map out the benefit-harm balance of fingolimod, drawing on data from a randomized controlled trial.

The study, like a detailed analysis of a desert ecosystem, reveals that fingolimod can effectively reduce relapses and slow disease progression in MS patients but also comes with a range of side effects. This underscores the need for careful consideration and individualised treatment approaches.

Navigating the Risks and Rewards of Fingolimod

This research provides crucial information for patients and healthcare providers considering fingolimod as a treatment for MS. It's like having a compass in the desert, guiding us toward making informed decisions about treatment options.

Personalizing MS Treatment

This research emphasizes the importance of individualised treatment for MS, carefully weighing the potential benefits and risks of each medication. It's a reminder that just as a camel adapts to the specific challenges of a particular desert, finding the right treatment for MS requires a personalized approach.

Dr.Camel's Conclusion

This study highlights the importance of weighing the benefits and harms of fingolimod in the treatment of MS. It's a reminder that finding the right treatment for MS requires a careful evaluation of both the potential rewards and risks, just like a camel navigating a treacherous desert landscape.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2021-05-14
Further Info :

Pubmed ID

32889373

DOI: Digital Object Identifier

10.1016/j.msard.2020.102464

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.